more

Pluristem Therapeutics, Inc. (PSTI)

(Delayed Data from NSDQ)

$0.65 USD

+0.01 (1.27%)

Updated May 3, 2019 04:13 PM ET

After-Market: $0.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

by Zacks Equity Research Published on July 14,2022

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal

by Zacks Equity Research Published on December 29,2021

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

by Zacks Equity Research Published on December 28,2021

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Are Options Traders Betting on a Big Move in Pluristem Therapeutics (PSTI) Stock?

by Zacks Equity Research Published on October 14,2020

Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.

PSTIPositive Net Change

medical

Pluristem Completes Enrollment in Phase I Hematology Study

by Zacks Equity Research Published on August 20,2020

Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.

biotechs

Has Pluristem Therapeutics (PSTI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on June 01,2020

Is (PSTI) Outperforming Other Medical Stocks This Year?

PSTIPositive Net Change

Is Pluristem Therapeutics (PSTI) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on May 15,2020

Is (PSTI) Outperforming Other Medical Stocks This Year?

PSTIPositive Net Change

Pluristem Therapeutics Inc. (PSTI) Shares March Higher, Can It Continue?

by Zacks Equity Research Published on May 01,2020

As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).

PSTIPositive Net Change

medical

Here's Why Momentum Investors Will Love Pluristem (PSTI)

by Zacks Equity Research Published on April 30,2020

Does Pluristem (PSTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

PSTIPositive Net Change

Has Pluristem Therapeutics (PSTI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on April 29,2020

Is (PSTI) Outperforming Other Medical Stocks This Year?

PSTIPositive Net Change

Biotech ETFs Gaining on Progress in Coronavirus Treatment

by Sweta Jaiswal, FRM Published on April 21,2020

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.